Purpose: To investigate whether TP53 mutation, 1p/19q codeletions, O 6 -methylguanylmethyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutation predict natural course of disease or response to radiotherapy or chemotherapy or both in low-grade glioma patients.
Introduction
Several molecular markers have been proposed as potential predictors of outcome in patients with World Health Organization (WHO) grade II gliomas, which comprise diffuse astrocytomas (A II), mixed oligoastrocytomas (OA II) and oligodendrogliomas (O II). The outcome has traditionally been considered to be more favorable in O II and less favorable in A II, whereas OA II has been attributed as an intermediate prognosis (1, 2) . Some molecular aberrations are linked to histologic subtypes of WHO grade II gliomas and may therefore be of diagnostic value, for example, TP53 mutations are more common in A II, whereas combined deletions of 1p and 19q (1p/19q deletion) are more common in OA II and O II.
The clinical relevance of these molecular changes has remained controversial. Thus, is has remained unclear whether it is the 1p/19q deletion or the oligodendroglial morphology that confers a less aggressive course of disease than A II. Moreover, within one histologic subtype of WHO grade II glioma, the clinical relevance of the molecular markers has remained controversial. Finally, it has proven difficult to distinguish prognostic significance, defined as overall better outcome irrespective of management, from predictive significance, defined as a better outcome provided a specific treatment is administered.
For instance, 1p/19q deletion resulting from an unbalanced translocation (3, 4) , preferentially in oligodendroglial tumors, were first associated with sensitivity to alkylating agent chemotherapy (5) and later to sensitivity to radiotherapy as well (6) . Eventually, we reported that the 1p/19q deletion loses its powerful prognostic impact if patients (with WHO grade II gliomas) receive no further radiotherapy or chemotherapy after surgery (7) , making the 1p/19q deletion a candidate predictive marker for prolonged progression-free survival (PFS) and overall survival (OS) in response to DNA-damaging treatments in general. Yet, neuroradiologic monitoring nevertheless revealed a slower spontaneous growth rate in untreated 1p/19q-deleted low-grade gliomas than in untreated 1p/ 19q-nondeleted tumors (8) .
In contrast, the prognostic or predictive role for TP53 mutations has remained controversial and no consistent association with response to therapy or overall outcome has been reported (9) (10) (11) (12) . Similarly, in contrast to the strong predictive and prognostic role for methylation of the promoter region of the O 6 -methylguanylmethyltransferase (MGMT) gene in newly diagnosed glioblastoma patients treated with temozolomide, no such role has been defined in other gliomas (13) . MGMT promoter methylation predicted a favorable outcome in WHO grade III anaplastic gliomas treated with either alkylating agent chemotherapy or radiotherapy (14, 15) , and its significance in WHO grade II gliomas remains unclear (16) .
The identification of isocitrate dehydrogenase 1 (IDH1) mutations in a minority of glioblastomas and pilocytic astrocytomas, but in the majority of WHO grade II and III gliomas (17) (18) (19) (20) , has dramatically altered our concepts of the origin and malignant progression of gliomas. In particular, it has become clear that most glioblastomas do not evolve from clinically silent lowgrade gliomas; second, IDH1 mutations have been confirmed as early mutations in low-grade gliomas (21) , which may facilitate gliomagenesis along different morphologic and molecular pathways, including astrocytomas more associated with TP53 mutations and oligodendrogliomas more associated with 1p/19q deletion. Moreover, IDH1 mutations are associated with younger age and better outcome within each glioma entity (22) (23) (24) (25) .
Here, we sought to evaluate the prognostic versus predictive relevance of molecular markers in WHO grade II gliomas and studied the 4 most prominent molecular markers thought to be involved in the development, progression, or both, of gliomas, TP53 mutation, 1p/ 19q deletion, MGMT promoter methylation, and IDH1 mutation in the tumor tissue of patients who received neither radiotherapy nor chemotherapy after first surgery (cohort A). We asked whether the status of these markers correlated with the time to the diagnosis of progressive disease (PD) and/or the first therapeutic reintervention, or with the survival from that reintervention. Results in cohort A were compared with findings in a second set of patients (cohort B) who received radiotherapy or chemotherapy immediately after the first surgical intervention.
Materials and Methods

Patient selection
The centers of the German Glioma Network (GGN) identified 89 patients with A II (n ¼ 40), OA II (n ¼ 23), or O II (n ¼ 26) operated on from 1991 to 2006 who had not received radiotherapy or chemotherapy after their first operation (cohort A). These patients were monitored until the end of follow-up or until therapeutic reintervention, which was based on the local diagnosis of PD documented by neuroradiologic criteria that conformed to Macdonald criteria (26) for contrast-enhancing lesions or similar adapted criteria for nonenhancing lesions and beyond. For comparison and possible validation, we studied a second group of 50 patients with A II (n ¼ 38), OA II (n ¼ 7), or O II (n ¼ 5) who were operated on from 1991 to 2009 and were treated with radiotherapy alone (n ¼ 25), chemotherapy with alkylating agents alone (n ¼ 21), or radiotherapy and alkylating agents (n ¼ 4) immediately after the establishment of the diagnosis (cohort B). Individual data for both cohorts are provided in Supplementary Table S1 .
Central reference pathology
Formalin-fixed, paraffin-embedded material was submitted from the local (neuro)pathologists of the GGN centers for an independent histopathologic review to the Brain Tumor Reference Center of the German Society of Neuropathology and Neuroanatomy in Bonn. All tumors were classified according to the WHO classification of tumors of the central nervous system (27) . In case of differences between local and central reference diagnoses, the reference diagnosis overruled the local diagnosis for data analysis.
Translational Relevance
Numerous studies have tried to assess the prognostic value of the molecular markers O 6 -methylguanylmethyltransferase (MGMT) promoter methylation, combined 1p/19q deletions, TP53 mutation, and isocitrate dehydrogenase 1 (IDH1) mutation in patients with low-grade gliomas. Currently, the marker status does not influence the choice of established treatment modalities for patients with low-grade gliomas. Moreover, it has remained unclear whether these markers reflect the natural course of disease or whether they predict response to radio-or chemotherapy. Here, we report that none of them are sensitive prognostic markers in patients with low-grade gliomas who do not receive adjuvant genotoxic treatment after surgery. IDH1 mutations assume a prognostic role when genotoxic treatments are administered. IDH1 mutation and 1p/19q deletion status allow to define 3 prognostically distinct subgroups of low-grade gliomas.
Molecular studies
Prior to the extraction of DNA from tumor tissues by standard methods, all tumor samples were examined by 2 experienced neuropathologists (C.H., A.v.D.) to ensure an estimated tumor cell content of 80% or more. The techniques to determine TP53 mutations by single-strand confirmation polymorphism analysis followed by direct sequencing (28) , MGMT promoter methylation by onestage methylation-specific PCR (ref. 29 ; detection of a band on agarose gel in the lane containing PCR products generated by methylation-specific primers was scored as positive), IDH1 or IDH2 mutations by direct sequencing (30) , and 1p/19q deletion by multiplex ligation-dependent probe amplification (7) 
Statistical analysis
The association of clinical data and molecular markers was analyzed by the c 2 test and Fisher's exact test. Because of the descriptive manner of these analyses, P values were not adjusted for multiple testing. PFS, OS, and survival from the first reintervention in cohort A were analyzed by log-rank test. PFS was calculated from the day of first surgery until tumor progression, death, or end of followup. OS was calculated from the day of first surgery until death or end of follow-up. Survival from first reintervention in cohort A was calculated from the diagnosis of PD until death or end of follow-up. Cox regression models were fitted to assess the independent impact of the molecular markers adjusting for age (>40 vs. 40), diagnosis (A II vs. pooled OA II and O II), and extent of resection (total vs. no total). Karnofsky performance score was not included for too many missing values. Data were analyzed by PASW Statistics 18 (version 18.0.0; SPSS, Inc.).
Results
Cohort A consisted of 60 males and 29 females. The median follow-up was 6.3 years. PD was diagnosed in 59 patients, and 17 patients have died. The estimated median PFS without radiotherapy or chemotherapy was 4.1 years (95% CI: 3.1-5.1). The median follow-up was 8.6 years for A II, 5.5 for OA II, and 6.1 for O II. PD was documented in 75.0% of A II patients (30 of 40), 65.2% of OA II patients (15 of 23), and 53.8% of O II patients (14 of 26). After diagnosis of PD, 5 patients had second surgery, 8 patients received radiotherapy alone, 25 patients received radiotherapy and alkylating agents, and 9 patients received alkylating agents alone; 4 patients died shortly after PD, 4 patients had follow-up of less than 3 months after PD, and 4 had no further treatment at a follow-up of 1.5 to 8.5 years. The median OS was 15.5 years for all patients, 17.8 years for pooled OA II and O II, and undetermined for A II because the probability of OS was greater than 50% (Supplementary Fig. S1 ).
Cohort B consisted of 29 males and 21 females. The median follow-up was 3.8 years. The initial treatment was radiotherapy alone in 25 patients, alkylating agent chemotherapy alone in 21 patients, and combined radiochemotherapy in 4 patients. PD was documented in 22 patients, and 8 patients died. The estimated median PFS with initial treatment was 6.1 years (95% CI: 2.1-10.1). The median follow-up was 3.1 years for A II patients and 4.4 years for patients with OA II or O II. PD was documented in 50% of A II patients (19 of 38) and 25% of patients with OA II or O II (3 of 12). The median OS was 13.6 years for all patients, 8.1 years for A II patients, and 13.6 years for OA II or O II patients.
Molecular data
The demographic data and clinical features pooled by both histology for cohort A patients and molecular marker status are summarized in Table 1 . Three patients with IDH1 mutations did not have the classical R132H mutations: We found 3 R132C mutations, 2 in OA II, and 1 in A II. Only 1 patient with OA II in cohort A had an IDH2 mutation. His data were analyzed within the group of patients with IDH1 mutant tumors. Patients with TP53 and IDH1 mutations were younger than patients without TP53 mutations. The other molecular markers were not linked to age. No molecular marker was linked to gender. Oligodendroglial histology was associated with 1p/19q deletion and less so with MGMT promoter methylation, whereas A II was associated with TP53 mutation. Patients with TP53 mutant tumors had more aggressive surgery than patients with TP53 wildtype tumors, an observation that is difficult to explain. Supplementary Table S2 shows these data for cohort B. The trends were similar to those for cohort A, with lower significance, presumably because of lower patient numbers, except for the association of the 1p/19q deletion with OA II and O II.
All 4 molecular markers were informative in 81 of 89 cohort A patients. Table 2 shows the interrelations between specific molecular markers. None of 4 alterations were found in 7 patients, 5 A II, and 2 OA II patients. IDH1 wild-type tumors were found in 15 patients: 9 A II, 4 OA II, 2 O II. Only one OA II patient had both TP53 mutation and 1p/19q deletion. A similar pattern based on larger subgroups emerged when cohorts A and B and OA II and O II were pooled (Supplementary Table S3 Figure 1 and Table 3 (part A) show PFS of cohort A patients by histology and molecular markers. None of the molecular markers were prognostic for PFS for all tumors pooled or for single histologic entities. There were interesting trends for prolonged PFS in O II and OA II favoring the absence of MGMT promoter methylation, but not the presence of 1p/19q deletion, and for prolonged PFS with IDH1 mutations in A II. Table 3 (part B) shows that IDH1 mutations were associated with longer survival from first PD or reintervention in the pooled group of patients with OA II or O II. Moreover, there was a trend for better survival with 1p/19q deletion in the entire cohort A and specifically in OA II/O II patients. Finally, the unfavorable trend of MGMT promoter methylation persisted. Sample sizes became too small to allow estimates on the role of specific treatments administered at reintervention.
Survival analyses
We also analyzed OS from the initial diagnosis as summarized in Table 3 (part C). Given the natural course of WHO grade II gliomas, the number of events is still small. However, IDH1 mutation emerged as the most powerful parameter of outcome when comparing 5-year survival rates.
For comparison and possible validation of the observations in cohort A patients summarized in Table 3 (parts B and C), we also analyzed PFS and OS in cohort B patients who were not observed after the first surgical intervention but treated with radiotherapy, chemotherapy, or both. Similar to cohort A [ 
Multivariate analyses
An overall analysis of the distribution of molecular changes and outcomes in our pooled sample of cohorts A and B allowed the distinction of 3 groups of patients: patients with IDH1 mutation and 1p/19q deletion, the majority of whom had OA II or O II; patients with IDH1 mutation, but no 1p/19q deletion, the majority of whom had A II; and patients without IDH1 mutation whose tumors corresponded to different histologies and who share a less favorable outcome ( Fig. 2A-C) . Table 4 . Survival analyses in cohort B Several models were built to assess prognostic factors for the time to PD, reintervention, or both, in cohort A. Each molecular marker was analyzed in separate models adjusted for age, diagnosis, and extent of resection. No molecular marker, not even IDH1 mutation, showed a significant interrelation with time to PD or reintervention (Fig. 2D) . In further separate models for each molecular marker, OS was also analyzed in cohort A (Fig. 2E) .
On the basis of the observed 3 groups of the combination of IDH1 mutation and 1p/19q status, an indicator variable was built and analyzed in further multivariate models for time to PD or reintervention [ Table S4 . Cohort A patients with IDH1 mutation and 1p/ 19q codeletion were considered as the reference group. Age and extent of resection were included in the model, as well therapy after PD (yes vs. no) for the analysis of survival from first PD or reintervention. Age older than 40 years was associated with a relevant increased risk for only moderately for IDH1 mutation and no 1p/19q codeletion (RR ¼ 1.4, P ¼ 0.648).
In the pooled cohorts A þ B, each molecular marker was also analyzed with adjustment for age, diagnosis, extent of resection, and adjuvant therapy after first surgery (yes vs. no). MGMT, 1p/19q codeletion, and TP53 each showed a nonsignificant association with OS. Only IDH1 mutations were significantly associated with OS (RR ¼ 0.3, P ¼ 0.022; Fig. 2F ). Analysis of OS, including the combination of IDH1 and 1p/19q status as indicator variables and adjusted for age and extent of resection, showed a strong effect of IDH1 wild-type status compared with IDH1 mutation and 1p/19q codeletion (RR ¼ 8.0, P ¼ 0.004). For the comparison of IDH1 mutation, but no 1p/19q codeletion, with IDH1 mutation and 1p/19q codeletion, an increased risk of death (RR= 2.3, P ¼ 0.260) was observed (data not shown).
Discussion
The number of clinical, histopathologic, and molecular prognostic markers to estimate the outcome of patients with various types of gliomas, including low-grade gliomas, is steadily increasing (2, 32) . In contrast, few studies have tried to distinguish markers that characterize the natural course of disease from markers that predict PFS and OS in response to specific therapeutic measures. The observation until first PD of surgically treated patients followed without adjuvant radiotherapy, or chemotherapy is the only way to determine whether a marker predicts outcome in the absence of adjuvant DNA-damaging treatment and is thus a prognostic marker independent of radiotherapy and chemotherapy. For instance, 1p/19q deletion is strongly predictive for prolonged PFS and OS in patients with anaplastic oligodendroglial tumors (WHO grade III) who are treated with radiotherapy or radiotherapy plus nitrosourea-based chemotherapy or temozolomide alone (14, 33, 34 ). Yet, 1p/19q deletion did not predict PFS in patients, mostly with WHO grade II oligodendroglial tumors, who were treated with surgery alone (7), suggesting a link between this molecular marker and response to genotoxic therapies.
We here extend this observation and report that TP53 mutation, 1p/19q deletion, MGMT promoter methylation, or IDH1 mutation is not a sensitive prognostic marker for PFS in patients with WHO grade II gliomas treated with surgery alone [Table 3 (part A) and Fig. 1 ]. In contrast, 1p/ 19q deletion and IDH1 mutation assumed prognostic relevance after reintervention in cohort A [ Table 3 (parts B and C)] and were prognostic for PFS in cohort B patients who were treated with radiotherapy, chemotherapy, or both, already at diagnosis (Table 4) .
IDH1 mutations have previously been linked to improved OS but not to response to temozolomide at progression after radiotherapy, in patients with low-grade astrocytomas in a Dutch study (35) , whereas a French study observed better response to temozolomide and better OS in patients with IDH1 mutant tumors (24) . We find that IDH1 mutant A II may have a less aggressive spontaneous behavior and observed that the differential outcome of IDH1 mutant versus IDH1 wild-type tumors becomes much more visible once tumor-specific treatment has been initiated [Tables 3 (parts B and C), 4, and 5, Supplementary Fig. S1 ]. Moreover, we confirm that IDH1 wild-type low-grade gliomas can be viewed as a distinct prognostic entity with inferior outcome (25) . In contrast, the prognostic role of IDH1 mutation in low-grade glioma patients has not been confirmed in all series. In fact, the largest series published so far reported 2 unexpected findings; first, an association of IDH1 mutations with older age and, second, a lack of correlation with outcome (36) . The unexpected suggestion of possibly shortened PFS in patients with WHO grade II oligodendroglial tumors with MGMT promoter methylation [ Table 3 (part A)] has a precedent in that a similar observation was made in a small cohort of diffuse astrocytoma patients from Japan (16) and is unexpected in view of the favorable prognostic role of MGMT promoter methylation in WHO grade III and IV gliomas (13) .
We acknowledge that our study has weaknesses. The sample size for each entity was small, the design was in part retrospective, and choice of treatment was not standardized. There was no central neuroradiologic review to confirm PD, and there were also no standardized criteria to monitor disease progression in these tumors until recently (37) . Cohort A is a selected group of patients with lowgrade gliomas because the treating physicians considered observation after surgery a reasonable strategy, but we tried to compensate for that by including a cohort B for comparison. Yet, this introduces a bias for the comparison of both groups because patients in cohort B were considered by their physicians to require adjuvant radiotherapy or chemotherapy after surgery. On the other hand, OS was long and comparable in both cohorts, indicating that the extent of bias between both cohorts is limited but that both cohorts represent favorable groups of patients with lowgrade gliomas. Table 2 and Supplementary Table S3 illustrate the likely molecular pathogenesis of low-grade gliomas. IDH1 mutations are early and therefore presumably important lesions. They give rise to the formation of oligodendroglial tumors in the face of 1p/19q codeletions and otherwise lead to A II. IDH1 wild-type tumors are less well understood and share a less favorable prognosis, irrespective of histology (Table 5 ). Yet, our data indicate that none of the biomarkers studied here are sensitive predictors of PFS for glioma patients in the absence of genotoxic treatment whereas the profound impact of IDH1 mutations on OS was confirmed. In this regard, our study may provide so far the strongest evidence for differential responsiveness to genotoxic therapy of IDH1 mutant versus IDH1 wild-type low-grade gliomas.
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